Heparin Market - Industry Growth, Trends, Future Demands and Forecast 2021-2030

(Market Stats News via Comtex)

The global heparin market size was valued US$ 11.3 Bn in 2020 and expected to reach US$ 20.1 billion by 2030 with a CAGR of 7.3% from 2021 to 2030. Heparin is an anti-coagulant generally derived from the bovine and porcine tissue. Besides, it is also extracted and characterized from whales, humans, mice, clams, shrimps, and fresh water mussel. Heparin is used in the treatment of clots, and the global market is impacted by various factors such as the high incidence rate of thromboembolism, advent of biosimilars, quality issues, and further research activities for introducing novel and safe heparin products. Introduction of new anti-coagulants such as rivaroxaban, dabigatran, and apixaban is detrimental for the growth of the heparin market.

Get the sample pages of [email protected] https://www.visionresearchreports.com/report/sample/35901

North America dominated the global heparin market in 2019 and the trend is anticipated to continue during the forecast period. Some of the key growth drivers of the global heparin market include an aging population, rising incidence of cancer and its associated clotting disorders, and an increase in the number of coagulation tests during pregnancy in the past few years. The CDC reported that the medical cost associated with venous thromboembolism (VTE) treatment in the U.S. is approximately US$ 10 billion each year.

Asia Pacific is likely to be a highly lucrative market for heparin and it is expected to expand at a high CAGR during the forecast period.

Rise in incidence of coagulation and renal disorders and Increasing government initiatives for preventive health care programs to Drive Market

  • Coagulation disorders such as venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, cause around 1.2 million deaths across the world each year. According to the CDC, an estimated 500,000 to 900,000 people are affected by VTE in the U.S. each year. Moreover, the number of deaths due to VTE in Europe is higher than deaths caused by AIDS, breast and prostate cancers, and highway accidents collectively.
  • A study published by Deutsches Arzteblatt International in 2013 revealed that the annual incidence rate of diagnosed VTE is 150 to 200 cases per 100,000 in Germany. In an acute phase, the mortality rate of pulmonary embolism (PE) in Germany is approximately 7% to 11% i.e., about 40,000 deaths because of PE in the country each year. The statistics above clearly indicate demand for safe, reliable, and affordable anticoagulants.
  • According to the CDC, one out of every three adult citizens in the U.S. suffers from hypertension, which is considered to be the second-largest risk factor for stroke, which is caused by a blood clot. Medication and lifestyle changes are effective and affordable; however, the overall rate of blood pressure control remains suboptimal. 'Million Hearts' is an initiative led by the U.S. Department of Health & Human Services and co-led by CDC and the Centers for Medicare and Medicaid Services. The committee aligns and coordinates its activities in order to achieve hypertension control rates above 70% through electronic health records, innovations in health information technology, and patient communication.

Low Molecular Weight Heparin Segment to Dominate Market

  • Based on product, the global heparin market has been divided into unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH).
  • Majority of the branded LMWH drugs in the global heparin market have gone off patent, thereby offering market access to generic manufacturers. A generic/biosimilar version of branded LMWH should be a replica with no structural alterations. There are two FDA-approved biosimilar products of Paris-based Sanofi S.A.'s Lovenox (enoxaparin), but none in Europe. Currently, the biosimilars market for LMWHs is driven by the U.S. as products under approval were considered generics and not biosimilars. This led to rapid approval of ANDA filings.
  • However, Ultra-low Molecular Weight Heparin (ULMWH) is expected to grow with the highest CAGR in the forecast period. ULMWHs are structurally similar to LMWHs with high anti-Xa and low anti-IIa activities, which leads to higher absorption and anticoagulant activity compared to LMWH. This is expected to propel the ULMWH segment throughout the forecast period.

Bovine to be Highly Lucrative Segment

  • In terms of source, the global heparin market has been classified into bovine and porcine.
  • Rise in demand for heparin to treat or prevent certain heart, blood vessel, and lung conditions is expected to fuel the porcine during the forecast period. However, Increase in demand in the emerging markets such as China, India, and Brazil is expected to drive the bovine during the forecast period

Parenteral Segment to Dominate Market

  • Based on formulation, the global heparin market has been divided into oral and parenteral.
  • Parenteral route is dominated the market in 2018 as it protects the drug from enzymatic degradation and hydrolysis. Unfractionated heparin and low molecular weight heparin are the most commonly used pharmacological agents in hospitals. The oral administration of unfractionated heparin (UFH) is inconvenient for patients. UFH needs to be administered parenterally.

Buy this premium research report, click [email protected] https://www.visionresearchreports.com/report/cart/35901 OR Call: +1 9197 992 333

North America to Dominate Global Market

  • In terms of region, the global heparin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global heparin market in 2018, followed by Europe.
  • High market share held by the North America region is attributable to technological developments in the production of heparin and the growing pharmaceutical industry in North America. The market in the region is projected to expand in the near future, owing to increase in the demand for heparin from patients suffering from deep vein thrombosis (DVT)
  • The Heparin market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027. This is primarily attributable to the increasing patient population and growing incidence of cancer and other chronic diseases in the region, which have led to increase in the demand for heparin products.

Competitive Landscape

  • The global Heparin market is fragmented in terms of number of players. Key players in the global market include Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Sanofi, Pfizer, Inc., LEO Pharma A/S, Aspen, Baxter International Inc., B. Braun Melsungen AG, Syntex S.A, among others

The global heparin market has been segmented as follows:

By Product

    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMWH)
    • Unfractionated Heparin (UFH)

By Source

    • Bovine
    • Porcine

By Formulation

    • Oral
    • Parenteral

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Table of Content

  1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

  1. Assumptions and Research Methodology
  2. Executive Summary: Global Heparin Market
  3. Market Overview

4.1. Introduction

4.1.1. Product Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Heparin Market Analysis and Forecast, 2017-2030

4.4.1. Market Revenue Projections (US$ Mn)

  1. Key Insights

5.1. Market Strategies adopted by Top Players

5.2. Snapshot - Brand Analysis

5.3. Porter's Five Forces Analysis

  1. Global Heparin Market Analysis and Forecast, by Product

6.1. Introduction & Definition

6.1.1. Key Findings / Developments

6.2. Global Heparin Market Value Forecast, by Product, 2017-2030

6.2.1. Low Molecular Weight Heparin (LMWH)

6.2.2. Ultra-low Molecular Weight Heparin (ULMWH)

6.2.3. Unfractionated Heparin (UFH)

6.3. Global Heparin Market Attractiveness, by Product

  1. Global Heparin Market Analysis and Forecast, by Source

7.1. Introduction & Definition

7.1.1. Key Findings / Developments

7.2. Global Heparin Market Value Forecast, by Source, 2017-2030

7.2.1. Bovine

7.2.2. Porcine

7.3. Global Heparin Market Attractiveness, by Source

  1. Global Heparin Market Analysis and Forecast, by Formulation

8.1. Introduction & Definition

8.1.1. Key Findings / Developments

8.2. Global Heparin Market Value Forecast, by Formulation, 2017-2030

8.2.1. Oral

8.2.2. Parenteral

8.3. Global Heparin Market Attractiveness, by Formulation

  1. Global Heparin Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Global Heparin Market Value Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. North America Heparin Market Attractiveness, by Region

  1. North America Heparin Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. North America Heparin Market Value (US$ Mn) Forecast, by Product, 2017-2030

10.2.1. Low Molecular Weight Heparin (LMWH)

10.2.2. Ultra-low Molecular Weight Heparin (ULMWH)

10.2.3. Unfractionated Heparin (UFH)

10.3. North America Heparin Market Value (US$ Mn) Forecast, by Source, 2017-2030

10.3.1. Bovine

10.3.2. Porcine

10.4. North America Heparin Market Value (US$ Mn) Forecast, by Formulation, 2017-2030

10.4.1. Oral

10.4.2. Parenteral

10.5. North America Heparin Market Value (US$ Mn) Forecast, by Country, 2017-2030

10.5.1. U.S.

10.5.2. Canada

10.6. North America Heparin Market Attractiveness Analysis

10.6.1. By Product

10.6.2. By Source

10.6.3. By Formulation

10.6.4. By Country

  1. Europe Heparin Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Europe Heparin Market Value (US$ Mn) Forecast, by Product, 2017-2030

11.2.1. Low Molecular Weight Heparin (LMWH)

11.2.2. Ultra-low Molecular Weight Heparin (ULMWH)

11.2.3. Unfractionated Heparin (UFH)

11.3. Europe Heparin Market Value (US$ Mn) Forecast, by Source, 2017-2030

11.3.1. Bovine

11.3.2. Porcine

11.4. Europe Heparin Market Value (US$ Mn) Forecast, by Formulation, 2017-2030

11.4.1. Oral

11.4.2. Parenteral

11.5. Europe Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2030

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Heparin Market Attractiveness Analysis

11.6.1. By Product

11.6.2. By Source

11.6.3. By Formulation

11.6.4. By Country/Sub-region

  1. Asia Pacific Heparin Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Asia Pacific Heparin Market Value (US$ Mn) Forecast, by Product, 2017-2030

12.2.1. Low Molecular Weight Heparin (LMWH)

12.2.2. Ultra-low Molecular Weight Heparin (ULMWH)

12.2.3. Unfractionated Heparin (UFH)

12.3. Asia Pacific Heparin Market Value (US$ Mn) Forecast, by Source, 2017-2030

12.3.1. Bovine

12.3.2. Porcine

12.4. Asia Pacific Heparin Market Value (US$ Mn) Forecast, by Formulation, 2017-2030

12.4.1. Oral

12.4.2. Parenteral

12.5. Asia Pacific Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2030

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Heparin Market Attractiveness Analysis

12.6.1. By Product

12.6.2. By Source

12.6.3. By Formulation

12.6.4. By Country/Sub-region

  1. Latin America Heparin Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Latin America Heparin Market Value (US$ Mn) Forecast, by Product, 2017-2030

13.2.1. Low Molecular Weight Heparin (LMWH)

13.2.2. Ultra-low Molecular Weight Heparin (ULMWH)

13.2.3. Unfractionated Heparin (UFH)

13.3. Latin America Heparin Market Value (US$ Mn) Forecast, by Source, 2017-2030

13.3.1. Bovine

13.3.2. Porcine

13.4. Latin America Heparin Market Value (US$ Mn) Forecast, by Formulation, 2017-2030

13.4.1. Oral

13.4.2. Parenteral

13.5. Latin America Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2030

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America Latin America

13.6. Latin America Heparin Market Attractiveness Analysis

13.6.1. By Product

13.6.2. By Source

13.6.3. By Formulation

13.6.4. By Country/Sub-region

  1. Middle East & Africa Heparin Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Middle East & Africa Heparin Market Value (US$ Mn) Forecast, by Product, 2017-2030

14.2.1. Low Molecular Weight Heparin (LMWH)

14.2.2. Ultra-low Molecular Weight Heparin (ULMWH)

14.2.3. Unfractionated Heparin (UFH)

14.3. Middle East & Africa Heparin Market Value (US$ Mn) Forecast, by Source, 2017-2030

14.3.1. Bovine

14.3.2. Porcine

14.4. Middle East & Africa Heparin Market Value (US$ Mn) Forecast, by Formulation, 2017-2030

14.4.1. Oral

14.4.2. Parenteral

14.5. Middle East & Africa Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2030

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Middle East & Africa Heparin Market Attractiveness Analysis

14.6.1. By Product

14.6.2. By Source

14.6.3. By Formulation

14.6.4. By Country/Sub-region

  1. Competition Landscape

15.1. Market Player - Competition Matrix (by Tier and Size of companies)

15.2. Market Share / Position Analysis, by Company, 2018

15.3. Competitive Business Strategies

15.4. Company Profiles

15.4.1. Dr. Reddy's Laboratories Ltd

15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.1.2. Growth Strategies

15.4.1.3. SWOT Analysis

15.4.2. Teva Pharmaceutical Industries Ltd

15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.2.2. Growth Strategies

15.4.2.3. SWOT Analysis

15.4.3. Fresenius SE & Co. KGaA

15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.3.2. Growth Strategies

15.4.3.3. SWOT Analysis

15.4.4. Sanofi

15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.4.2. Growth Strategies

15.4.4.3. SWOT Analysis

15.4.5. Pfizer, Inc.

15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.5.2. Growth Strategies

15.4.5.3. SWOT Analysis

15.4.6. LEO Pharma A/S

15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.6.2. Growth Strategies

15.4.6.3. SWOT Analysis

15.4.7. Aspen

15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.7.2. Growth Strategies

15.4.7.3. SWOT Analysis

15.4.8. Baxter International Inc.

15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.8.2. Growth Strategies

15.4.8.3. SWOT Analysis

15.4.9. B. Braun Melsungen AG

15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.9.2. Growth Strategies

15.4.9.3. SWOT Analysis

15.4.10. Syntex S.A

15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.4.10.2. Growth Strategies

15.4.10.3. SWOT Analysis

Buy this premium research report, click [email protected] https://www.visionresearchreports.com/report/cart/35901 OR Call: +1 9197 992 333

The post Heparin Market - Industry Growth, Trends, Future Demands and Forecast 2021-2030 appeared first on Market Stats News.

comtex tracking

COMTEX_388142206/2746/2021-06-11T10:09:21